Areas of interest (AOI) & competitive research grants

We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Immunology - Cendakimab Jan 9, 2024 Jan 29, 2024 Mar 7, 2024
Cardiovascular – CAMZYOS (Mavacamten) Feb 23, 2024 Mar 04, 2024 Apr 11, 2024
Immunology – Sotyktu (Deucravacitinib) – Dermatology Feb 26, 2024 Mar 25, 2024 Apr 25, 2024


Mavacamten (CAMZYOS) ISR Areas of Interest – RFP#1 2024
 

Obstructive HCM diagnosis and management​

  • Earlier diagnostic approach to the at-risk population​
  • Diagnosis and management may include:  ​
    • Imaging, and correlation with clinical and trial endpoints.​
    • Reducing physician's/Patient's burden and improving satisfaction.​
    • Patient Journey: Initial interaction to ongoing care and follow-up.​

CAMZYOS echo monitoring​

  • Assess the benefits of innovative Echo technology in diagnosis, monitoring, workflow, access, coordination of care, and health equity in correlation with CAMZYOS label.​

Clinical use of CAMZYOS​

  • In special populations (minorities, elderly, comorbidities, socio-demographic inequities, Sports participation)​
  • CAMZYOS use in patients with milder symptoms (within the label-indicated population)

Implementation of best practices​

  • Decision-making support to include patient-preference​.
  • Approaches to improve patient and provider experience with CAMZYOS and lead to optimal results.​
  • Approaches that incorporate technology to streamline the process.

*Interventional and observational projects are acceptable, including new approaches to real-world data.​

 

Out of Scope: 

  • Off label (asymptomatic obstructive HCM; non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data. Myosin genotyping; re-analysis of clinical trial data.​
  • No real-world data​
  • No Biomarker data ​
  • Pediatric populations​
  • Viz-AI algorithm​

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Begin a new application